menu
    • menu
    [{"orgOrder":0,"company":"Actor Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH AFRICA","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Glycine","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Actor Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Gel","sponsorNew":"Actor Pharma \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Actor Pharma \/ Cipla"}]

    Find Clinical Drug Pipeline Developments & Deals by Actor Pharma

    Menu

    Actor Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Actor Pharma

    South Africa arrow
    ICHH-25
    Not Confirmed

    Actor Pharma

    South Africa arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Glycine,Calcium

    Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

    Study Phase : Approved

    Sponsor : Cipla

    Deal Size : $48.6 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Cipla to Acquire South Africa-based Actor Pharma

    Details : Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.

    Product Name : Nozohaem

    Product Type : Small molecule

    Upfront Cash : $48.6 million

    September 05, 2023

    Lead Product(s) : Glycine,Calcium

    Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

    Highest Development Status : Approved

    Sponsor : Cipla

    Deal Size : $48.6 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth